Enliven Therapeutics, Inc. (ELVN)
NasdaqGS
Price as at 1 Oct 2026, 04:48 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Enliven Therapeutics, Inc. trades at $45.84. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$105.00M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$27.01M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$20.88M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$15.51M · 0.0% of book
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$2.04M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ELVN?
6 of the institutions we track reported a position in ELVN in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ELVN data?
Fundamentals for ELVN come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 04:48 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ELVN, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.